<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1236469</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2023.1236469</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Lomerizine attenuates LPS-induced acute lung injury by inhibiting the macrophage activation through reducing Ca<sup>2&#x2b;</sup> influx</article-title>
<alt-title alt-title-type="left-running-head">Song et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2023.1236469">10.3389/fphar.2023.1236469</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Song</surname>
<given-names>Yunduan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Gou</surname>
<given-names>Yusen</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Gao</surname>
<given-names>Jiameng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Dongxin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Haibo</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Wenjuan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/165271/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Qian</surname>
<given-names>Feng</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/581365/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xu</surname>
<given-names>Ajing</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1929570/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Shen</surname>
<given-names>Yao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Respiratory and Critical Care Medicine</institution>, <institution>Shanghai Pudong Hospital</institution>, <institution>Fudan University Pudong Medical Center</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Clinical Laboratory</institution>, <institution>Tongren Hospital</institution>, <institution>Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Shanghai Frontiers Science Center of Drug Target Identification and Delivery</institution>, <institution>School of Pharmacy</institution>, <institution>Shanghai Jiao Tong University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Clinical Pharmacy</institution>, <institution>Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/856432/overview">Xiaopeng Li</ext-link>, Michigan State University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2124855/overview">Qianjiang Hu</ext-link>, University of Pittsburgh, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2004528/overview">Daoqin Zhang</ext-link>, Sleep Medicine Center, Stanford Healthcare, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Yao Shen, <email>20594@shpdh.org</email>; Ajing Xu, <email>xuajing@xinhuamed.com.cn</email>; Feng Qian, <email>fengqian@sjtu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1236469</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>06</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>08</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Song, Gou, Gao, Chen, Zhang, Zhao, Qian, Xu and Shen.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Song, Gou, Gao, Chen, Zhang, Zhao, Qian, Xu and Shen</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening lung diseases with high mortality rates, predominantly attributable to acute and severe pulmonary inflammation. Lomerizine (LMZ) is a calcium channel blocker previously used in preventing and treating migraine. Here, we found that LMZ inhibited inflammatory responses and lung pathological injury by reducing pulmonary edema, neutrophil infiltration and pro-inflammatory cytokine production in lipopolysaccharide (LPS)-induced ALI mice. In <italic>vitro</italic> experiments, upon treating with LMZ, the expression of interleukin (IL)-1&#x3b2;, IL-6 and tumor necrosis factor (TNF)-&#x3b1; was attenuated in macrophages. The phosphorylation of p38 MAPK, ERK1/2, JNK, and NF-&#x3ba;B p65 was inhibited after LMZ treatment. Furthermore, LPS-induced Ca<sup>2&#x2b;</sup> influx was reduced by treating with LMZ, which correlated with inhibition of pro-inflammatory cytokine production. And L-type Ca<sup>2&#x2b;</sup> channel agonist Bay K8644 (BK) could restore cytokine generation. In conclusion, our study demonstrated that LMZ alleviates LPS-induced ALI and is a potential agent for treating ALI/ARDS.</p>
</abstract>
<kwd-group>
<kwd>lomerizine</kwd>
<kwd>acute lung injury</kwd>
<kwd>calcium</kwd>
<kwd>macrophage</kwd>
<kwd>cytokine</kwd>
<kwd>inflammation</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Respiratory Pharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Acute lung injury (ALI) is an inflammatory disease mainly characterized by alveolar capillary injury, diffuse interstitial, alveolar edema, and hypoxic respiratory insufficiency after severe infection, trauma, shock and other pulmonary attack (<xref ref-type="bibr" rid="B6">Butt et al., 2016</xref>). Acute respiratory distress syndrome (ARDS), the more serious form of ALI, is a life-threatening lung disease with high mortality (<xref ref-type="bibr" rid="B38">Rubenfeld et al., 2005</xref>; <xref ref-type="bibr" rid="B30">Matthay et al., 2019</xref>). Patients suffering from ALI/ARDS have increased sharply since the global outbreak of novel coronavirus pneumonia (COVID-19) in 2019 (<xref ref-type="bibr" rid="B12">Gao et al., 2021</xref>; <xref ref-type="bibr" rid="B32">Meyer et al., 2021</xref>; <xref ref-type="bibr" rid="B35">Pfortmueller et al., 2021</xref>). Mechanical ventilation remains the only supportive therapy for ALI. However, it does not enhance the quality of life for ALI patients and still carries side effects, including lung infection and lung injury (<xref ref-type="bibr" rid="B14">Gattinoni et al., 2016</xref>; <xref ref-type="bibr" rid="B13">Gattinoni et al., 2017</xref>; <xref ref-type="bibr" rid="B10">Fan et al., 2018</xref>). Nowadays, no effective drugs have been reported for treating acute lung injury (<xref ref-type="bibr" rid="B4">Bernard et al., 1987</xref>; <xref ref-type="bibr" rid="B45">Steinberg et al., 2006</xref>). Therefore, the development of new drugs for ALI therapy is urgent.</p>
<p>Uncontrollable inflammation is the main factor in acute lung injury, contributed from endothelial, epithelial, and alveolar structure injury, and inflammatory cells infiltration. Macrophages play a crucial role in regulating inflammatory responses in ALI/ARDS (<xref ref-type="bibr" rid="B53">Wynn et al., 2013</xref>; <xref ref-type="bibr" rid="B50">Watanabe et al., 2019</xref>). Macrophages can be activated to phenotype of M1 or M2 in response to environmental signals from the microenvironment (<xref ref-type="bibr" rid="B40">Saqib et al., 2018</xref>). M1 macrophages play a pro-inflammatory role by releasing variety of pro-inflammatory cytokines including interleukin (IL)-1&#x3b2;, IL-6 and tumor necrosis factor (TNF)-&#x3b1; (<xref ref-type="bibr" rid="B22">Lee et al., 2021</xref>). While M2 macrophages synthesize and release anti-inflammatory cytokines including transforming growth factor (TGF)-&#x3b2; and IL-10, contributing to anti-inflammatory response and tissue remodeling. The transformation of macrophage function is closely related to the initiation and development of pneumonia (<xref ref-type="bibr" rid="B16">Guan et al., 2023</xref>). During the pathology of ALI, toll-like receptors (TLRs) are activated by pathogen-associated molecular patterns in macrophages (<xref ref-type="bibr" rid="B2">Arora et al., 2019</xref>). The macrophages immediately shift toward M1 phenotype and release various pro-inflammatory cytokines. And then, these pro-inflammatory cytokines recruit neutrophils into the lung and alveolar lumens (<xref ref-type="bibr" rid="B21">Kolaczkowska and Kubes, 2013</xref>). Therefore, macrophage polarization is a practical and promising target for ALI treatment.</p>
<p>Lomerizine (LMZ), also known as KB-2796, is a calcium channel blocker, whose chemical name is 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl) piperazine. It was first listed in Japan in 1999, and the product was named Migsis and Teranas (<xref ref-type="bibr" rid="B15">Gaudilliere and Berna, 2000</xref>). LMZ possesses better selectivity on cerebrovascular, with a strong protective effect on brain tissue with fewer side effects on the heart and central nervous system than earlier migraine drugs. It is normally used to treat migraine in clinical practice through blocking T-type and L-type calcium channels. Drugs that block calcium channels have been verified to reduce inflammation in previous studies (<xref ref-type="bibr" rid="B42">Shima et al., 2008</xref>; <xref ref-type="bibr" rid="B17">Huang et al., 2014</xref>). Das et al. found that L-type Ca<sup>2&#x2b;</sup> channel (LTCC) blockers amlodipine and verapamil exert anti-inflammatory effects by inhibiting the expression of fibrinogen in macrophages, which inhibits macrophage recruitment (<xref ref-type="bibr" rid="B9">Das et al., 2009</xref>). Another LTCC blocker, nifedipine, has been shown to inhibit fibroblast activation by antagonizing the activity of mineralocorticoid receptors (<xref ref-type="bibr" rid="B29">Matsui et al., 2010</xref>). However, the therapeutic effect of LMZ in ALI has not been reported.</p>
<p>In this study, we demonstrated that LMZ attenuates LPS-induced ALI by decreasing pro-inflammatory cytokines expression through blocking calcium influx, which regulated by mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-&#x3ba;B) signaling pathways. The results revealed that LMZ has potential as a therapeutic agent for ALI/ARDS.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Compound and reagents</title>
<p>Lomerizine was purchased from Absin Bioscience Inc. (Shanghai, China). Lipopolysaccharide (LPS) was purchased from Sigma-Aldrich (St. Louis, United States). Dexamethasone was purchased from Thermo Fisher Scientific (Waltham, MA, United States). Hematoxylin and eosin (H&#x26;E) staining kit was purchased from Abcam (Waltham, Boston, United States). Dulbecco&#x2019;s Modified Eagle Medium (DMEM) and macrophage colony-stimulating factor (M-CSF) was purchased from Thermo Fisher Scientific (Waltham, MA, United States). Penicillin-streptomycin solution (Pen Strep) was purchased from Yeasen Biotechnology Co., Ltd. (Shanghai, China). Fetal Bovine Serum (FBS) was purchased from Cegrogen Biotech (Wupperweg, Germany).</p>
<p>Primers were synthesized by Hua Gene Biotech Co., Ltd. (Shanghai, China). The primary antibody against I&#x3ba;B-&#x3b1; was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States). Primary antibodies against iNOS, phospho-NF-&#x3ba;B p65 (Ser536) Rabbit mAb, NF-kappaB p65 Rabbit mAb, phospho-p38 MAPK (Thr180/Tyr182) XP Rabbit mAb, p38 MAPK XP Rabbit mAb, phospho-SAPK/JNK (Thr183/Tyr185) Rabbit mAb, SAPK/JNK Antibody, Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) Antibody, p44/42 MAPK (ERK1/2) Rabbit mAb, and &#x3b2;-Actin Rabbit Antibody were purchased from Cell Signaling Technology (Danvers, MA, United States).</p>
</sec>
<sec id="s2-2">
<title>2.2 Animals and treatment</title>
<p>C57BL/6 mice were purchased from JST Laboratory Animal Co., Ltd. (Shanghai, China). The mice were bred under sterile and temperature-controlled conditions for 12&#xa0;h of light and dark cycle. Mice had free access to water and feed in the experimental period. Mice were housed under specific pathogen-free conditions at the Laboratory Animal Center of Shanghai Jiao Tong University. All procedures involving mice were approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University (A2018075).</p>
<p>Thirty male mice aged 8&#x2013;10&#xa0;weeks were selected to establish acute lung injury models. The mice were randomly divided into six groups: PBS group, LPS treatment group, dexamethasone (DEX) treatment group, low dose lomerizine (LMZ) group (10&#xa0;mg/kg), medium dose LMZ group (20&#xa0;mg/kg), and high dose LMZ group (40&#xa0;mg/kg). In PBS group, the neck skin of mice was dissected and sutured. The other groups were given 5&#xa0;mg/kg LPS via intratracheal administration. Moreover, DEX or various doses of LMZ were injected intraperitoneally 1&#xa0;h after LPS was administered.</p>
</sec>
<sec id="s2-3">
<title>2.3 Bronchoalveolar lavage fluid collection and analysis</title>
<p>After 6&#xa0;h of LPS stimulation, mice were anesthetized, and the trachea was exposed with scissors, then a small cut was gently made in the trachea and a needle was inserted, followed by the injection of 1&#xa0;mL of cooled PBS, waited for 10&#xa0;s and then the bronchoalveolar lavage fluid (BALF) was slowly withdrawn. And collected BALF was put on ice and then centrifuged at 4&#xb0;C for 500 rcf for 5&#xa0;min (<xref ref-type="bibr" rid="B52">Wu et al., 2021</xref>). The total number of cells was counted with a hemocytometer. And the supernatant was analyzed for total protein using a EpiZyme BCA kit (Shanghai, China).</p>
</sec>
<sec id="s2-4">
<title>2.4 Flow cytometry assay</title>
<p>The suppernatant after centrifugation of BALF was added 300&#xa0;&#x3bc;L red blood cell lysate (Sangon biotech, China) and mixed well, and rested on ice for 5&#xa0;min, 3&#xa0;mL PBS was added, followed by 500 rcf centrifugation at 4&#xb0;C for 5&#xa0;min. The supernatant was discarded and 100&#xa0;&#x3bc;L of PBS containing 2% FBS was added to the supernatant for 30&#xa0;min. The detectable antibodies were then added and incubated for 30&#xa0;min. At the end of the incubation, the supernatant was mixed with 1&#xa0;mL of PBS and centrifuged at 500 rcf for 5&#xa0;min, then the supernatant was discarded and resuspended in 150&#xa0;&#x3bc;L of PBS. For neutrophils staining, anti-Ly-6G (clone 1A8, Cat. 551460) was used. For alveolar macrophage staining, PerCP/Cy5.5-F4/80, PE-CD11c, and FITC-MHC class II (I-A/I-E) antibodies were used. All flow cytometric antibodies were obtained from BD Bioscience (San Jose, CA, United States).</p>
</sec>
<sec id="s2-5">
<title>2.5 Enzyme-linked immunosorbent assay</title>
<p>Supernatants from BALF centrifugation and cell culture supernatants from BMDMs were collected and subsequently assayed for cytokine expression using ELISA kits (R&#x26;D System, Minneapolis, MN, United States) according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2-6">
<title>2.6 Histopathology</title>
<p>The lung tissue was removed from the mouse and soaked in deionized water containing 4% paraformaldehyde for 24&#xa0;h. The lung tissue was then wrapped in paraffin and cut into 10&#xa0;&#x3bc;m slices with a slicer after the paraffin had solidified. The slices were stained with H&#x26;E staining kits, and images were pictured with an Olympus microscope (BX53, Tokyo, Japan).</p>
</sec>
<sec id="s2-7">
<title>2.7 Cell culture of BMDMs</title>
<p>Euthanized mice were immersed in 75% ethanol for 2&#xa0;min, then the skin was cut along the abdominal cavity to expose the lower limbs, and the femur and tibia were removed and transferred to DMEM containing 1% Pen Strep. The bones were held with forceps and then the ends were cut with scissors, and 3&#xa0;mL of cold PBS was injected into the bones with a syringe, and the cells were collected below in a 50&#xa0;mL centrifuge tube. The collected cells were centrifuged at 500 rcf for 5&#xa0;min, the supernatant was discarded and subsequently resuspended in complete medium. Cells were cultured in DMEM supplemented with 10% Fetal Bovine Serum (FBS), 1% Penicillin-streptomycin solution (Pen Strep), and 10&#xa0;ng/mL M-CSF. After 5 days of culturing, cells were planted. BMDMs were pre-treated with LMZ for 30&#xa0;min and then challenged with 100&#xa0;ng/mL LPS for 30&#xa0;min.</p>
</sec>
<sec id="s2-8">
<title>2.8 Real-time polymerase chain reaction</title>
<p>Trizol purchased from Invitrogen (CA, United States) to extract the total RNA from cell and tissue samples, and the Nano-Drop 2000 micro-spectrophotometer was used for RNA quantification. The cDNA was prepared by the reverse transcription according to the instructions of the Toyobo reverse transcription kit (Toyobo, Osaka, Japan) and amplified by SYBR Green RT-PCR Master Mix kit (Toyobo, Osaka, Japan) on the StepOne Plus system (Thermo Fisher Scientific, Waltham, MA, United States). Glyceraldehyde-3-Phosphate Dehydrogenase (<italic>Gapdh</italic>) to test the gene expression data and normalize mRNA levels of different inflammatory factors. The primer sequences used in the reaction are listed in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Specific primer sequences used for RT-PCR.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Gene</th>
<th align="left">Forward primer</th>
<th align="left">Reverse primer</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<italic>Gapdh</italic>
</td>
<td align="left">5&#x2032;-CAT&#x200b;CAC&#x200b;TGC&#x200b;CAC&#x200b;CCA&#x200b;GAA&#x200b;GAC&#x200b;TG-3&#x2032;</td>
<td align="left">5&#x2032;-ATG&#x200b;CCA&#x200b;GTG&#x200b;AGC&#x200b;TTC&#x200b;CCG&#x200b;TTC&#x200b;AG-3&#x2032;</td>
</tr>
<tr>
<td align="left">
<italic>Tnf&#x3b1;</italic>
</td>
<td align="left">5&#x2032;-TGG&#x200b;ACC&#x200b;TTC&#x200b;CAG&#x200b;GAT&#x200b;GAG&#x200b;GAC&#x200b;A-3&#x2032;</td>
<td align="left">5&#x2032;-GCC&#x200b;ATA&#x200b;GAA&#x200b;CTG&#x200b;ATG&#x200b;AGA&#x200b;GGG&#x200b;AG -3&#x2032;</td>
</tr>
<tr>
<td align="left">
<italic>Il1&#x3b2;</italic>
</td>
<td align="left">5&#x2032;-TGG&#x200b;ACC&#x200b;TTC&#x200b;CAG&#x200b;GAT&#x200b;GAG&#x200b;GAC&#x200b;A-3&#x2032;</td>
<td align="left">5&#x2032;-GTT&#x200b;CAT&#x200b;CTC&#x200b;GGA&#x200b;GCC&#x200b;TGT&#x200b;AGT&#x200b;G-3&#x2032;</td>
</tr>
<tr>
<td align="left">
<italic>Il6</italic>
</td>
<td align="left">5&#x2032;-TAC&#x200b;CAC&#x200b;TTC&#x200b;ACA&#x200b;AGT&#x200b;CGG&#x200b;AGG&#x200b;C-3&#x2032;</td>
<td align="left">5&#x2032;-CTG&#x200b;CAA&#x200b;GTG&#x200b;CAT&#x200b;CAT&#x200b;CGT&#x200b;TGT&#x200b;TC-3&#x2032;</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-9">
<title>2.9 Western blot</title>
<p>Protein with equal concentrations in each group were mixed with 5&#xd7; protein loading buffer (Sigma-Aldrich, United States) and incubated at 99&#xb0;C for 10&#xa0;min. Then running the sample by 15% SDS-PAGE gels before being subsequently transferred to NC membranes (GE, United States). The immnunoblots were incubated with 5% milk at room temperature for 0.5&#x2013;1&#xa0;h, followed by an incubation at 4&#xb0;C with primary antibodies overnight. After rinsing the membranes five times with TNET buffer (5&#xa0;min of each), incubated with IgG (H &#x2b; L)-HRP secondary antibodies (Santa Cruz, United States) for 1&#x2013;2&#xa0;h. The band densities were detected using an LumiBest ECL solution from Shanghai Sharebio Biotechnology (Shanghai, China) and Bio-Rad Laboratories (BIO-RAD, United States). ImageJ Software was using for analysis of the results.</p>
</sec>
<sec id="s2-10">
<title>2.10 Myeloperoxidase activity</title>
<p>For the purpose of measuring myeloperoxidase (MPO) activity, the lung tissues of mice were weighted and homogenized. Referring to the Myeloperoxidase (MPO) assay kit from Nanjing Jiancheng (Nanjing, China), the activity of MPO was measured.</p>
</sec>
<sec id="s2-11">
<title>2.11 Determination of NO level</title>
<p>BMDMs were plated and pre-treated with LMZ 0, 3, 10 or 30&#xa0;&#x3bc;M for 30&#xa0;min and challenged with 100&#xa0;ng/mL LPS for 24&#xa0;h to collect the supernatant. Nitric oxide (NO) levels in BMDMs were tested by NO Kit (Beyotime, Shanghai, China).</p>
</sec>
<sec id="s2-12">
<title>2.12 Ca<sup>2&#x2b;</sup> influx imaging</title>
<p>The pre-cultured BMDMs were washed three times with HBSS. The Fluo-4-AM 4&#xa0;&#x3bc;M working solution (Shanghai Sharebio Biotechnology, China) was added to the cells and incubated at 37&#xb0;C for 40&#xa0;min. Then removed Fluo-4-AM green-fluorescent calcium indicator and rewashed the cells with HBSS. The cells were then incubated with or without LMZ (30&#xa0;&#x3bc;M) at 37&#xb0;C for 10&#xa0;min before exposed to LPS (1&#xa0;&#x3bc;g/mL) and Ca<sup>2&#x2b;</sup> channel agonist Bay K8644 (BK, 10&#xa0;&#x3bc;M). Fluorescent Ca<sup>2&#x2b;</sup> was detected under a laser-scanning confocal fluorescence microscope (Zeiss LSM 900, Germany). Fluo-4-AM was performed for 10&#xa0;min (6s intervals) via fluorescence excited at 494&#xa0;nm and collect fluorescence emission at 516&#xa0;nm for calcium imaging.</p>
</sec>
<sec id="s2-13">
<title>2.13 Statistical analysis</title>
<p>Data shown mean &#xb1; standard deviation (s.d.) of one representative experiment out of three independent <italic>in vivo</italic> experiments and shown mean &#xb1; standard error of the mean (s.e.m) of three independent <italic>in vitro</italic> experiments. All Data were analyzed using one-way ANOVA (Tukey&#x2019;s test) with Prism version 9 (GraphPad Software, San Diego, CA, United States). <italic>p</italic>-values &#x3c;0.05 were considered to be statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Result</title>
<sec id="s3-1">
<title>3.1 Lomerizine attenuates LPS-induced acute lung injury</title>
<p>To determine the function of lomerizine (LMZ) on acute lung injury (ALI), We established lipopolysaccharide (LPS)-induced ALI mice and treated them with LMZ and dexamethasone (DEX) (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Hematoxylin and eosin (HE) staining of lung tissue showed alveolar wall thickening, lung tissue destruction and infiltration of inflammation cells deteriorated in the LPS-treated lung tissue (<xref ref-type="fig" rid="F1">Figure 1C</xref>). However, LMZ treatment significantly reduced the infiltration of inflammatory cells and protected alveolar structures in LPS-induced ALI mice. The protein concentration in bronchoalveolar lavage fluid (BALF) of ALI mice was increased significantly compared with that of the PBS group (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Meanwhile, the number of cells in BALF of LPS-induced mice was increased significantly (<xref ref-type="fig" rid="F1">Figure 1E</xref>). Myeloperoxidase (MPO) activity was measured as a marker of neutrophil infiltration. LPS-challenged mice showed a significant increase in MPO activity in lung tissue, while LMZ treatment significantly inhibited MPO activity (<xref ref-type="fig" rid="F1">Figure 1F</xref>). We detected Ly6G-positive number to assess the infiltration of neutrophils in lung tissue (<xref ref-type="fig" rid="F1">Figure 1G</xref>). LMZ treatment significantly decreased Ly6G-positive neutrophils in BALF (<xref ref-type="fig" rid="F1">Figure 1H</xref>). These data indicated that LMZ mitigates LPS-induced ALI.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Lomerizine (LMZ) attenuated lipopolysaccharide (LPS)-induced acute lung injury (ALI). <bold>(A)</bold> Chemical structure of LMZ. <bold>(B)</bold> Experimental schematic of LPS-induced mice receiving treatment of LMZ. 30 mice were randomly assigned into PBS group, LPS group (5&#xa0;mg/kg), LMZ group (10, 20 and 40&#xa0;mg/kg) and dexamethasone group (DEX, 5&#xa0;mg/kg). After anesthesia, mice were intraperitoneally injected with different concentrations of LMZ and DEX 1&#xa0;h after intratracheal injection of LPS and subsequent experiments were performed 5&#xa0;h later. <bold>(C)</bold> Representative images of lung sections were taken by orthomosaic microscopic observation. LPS-induced bronchoalveolar lavage fluid (BALF) in mice was detected to validate the ALI model. <bold>(D)</bold> Total protein levels in BALF. <bold>(E)</bold> Total cell counts in BALF. <bold>(F)</bold> Myeloperoxidase (MPO) activity in the lungs. <bold>(G)</bold> Statistical analysis of <xref ref-type="fig" rid="F1">Figure 1H</xref>. <bold>(H)</bold> Levels of the neutrophil marker Gr-1 in BALF were examined by flow cytometry. Data shown mean &#xb1; s.d. of one representative experiment out of three independent experiments. n &#x3d; 5 per group, <italic>p</italic>-values were calculated by one-way ANOVA (Tukey&#x2019;s test). &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-14-1236469-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>3.2 Lomerizine inhibits macrophage activation in LPS-induced mice through NK-&#x3ba;B and MAPK signal pathways</title>
<p>To further investigate the phenotype of LMZ in alleviating LPS-induced ALI, we measured the expression levels of pro-inflammatory cytokines of LPS-induced mice in BALF by RT-PCR. The mRNA expression levels of TNF-&#x3b1;, IL-1&#x3b2; and IL-6 were significantly upregulated by LPS treatment, while suppressed by LMZ treatment dose-dependently, which was similar with dexamethasone (DEX) (<xref ref-type="fig" rid="F2">Figures 2A&#x2013;C</xref>). Consistently, the enzyme-linked immunosorbent assay (ELISA) results showed that LMZ dose-dependently reduced the protein levels of TNF-&#x3b1;, IL-1&#x3b2; and IL-6 induced by LPS (<xref ref-type="fig" rid="F2">Figures 2D&#x2013;F</xref>). Macrophages play a critical role in the pulmonary inflammation and are involved in tissue injury and inflammatory recovery processes (<xref ref-type="bibr" rid="B7">Chen et al., 2001</xref>). To determine whether LMZ alleviates macrophage activation, we stained the cells from BALF with PE-CD11c, PerCP-Cy5.5-F4/80 and FITC-MHC class II antibodies. Alveolar macrophages can be considered as CD11c<sup>&#x2b;</sup> F4/80<sup>&#x2b;</sup> cells. MHC class II reflected activation of macrophage after LPS stimulation. Flow cytometry analysis revealed an increased percentage of CD11c<sup>&#x2b;</sup> F4/80<sup>&#x2b;</sup> MHC class &#x2161;<sup>&#x2b;</sup> cells after LPS stimulation in BALF which was restored after LMZ treatment (<xref ref-type="fig" rid="F2">Figure 2G</xref>). Moreover, compared to PBS group, the percentage of MHC class &#x2161;-positive cells were approximately 9-fold increase in LPS group, but only about 2-fold increase in LPS and LMZ co-administration group (<xref ref-type="fig" rid="F2">Figure 2H</xref>). These results indicated that LMZ inhibits macrophage activation in LPS-induced mice.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Lomerizine (LMZ) reduced the production and secretion of pro-inflammatory cytokines in lipopolysaccharide (LPS)-induced acute lung injury mice. LMZ (0, 10, 20 and 40&#xa0;mg/kg) or DEX (5&#xa0;mg/kg) treatments were administered 1&#xa0;h after LPS stimulation (5&#xa0;mg/kg). <bold>(A&#x2013;C)</bold> The mRNA levels of <italic>Tnf&#x3b1;, Il1&#x3b2;</italic> and <italic>Il6</italic> were examined in mice lung tissue by real-time polymerase chain reaction (RT-PCR). <bold>(D&#x2013;F)</bold> BALF was collected and ELISA kits detected the protein expression level of each pro-inflammatory cytokines. <bold>(G)</bold> The percentage of alveolar macrophages in BALF after LMZ (40&#xa0;mg/kg) treatment were examined by flow cytometry. <bold>(H)</bold> The percentage of MHC class &#x2161;-positive alveolar macrophages in BALF. Data shown mean &#xb1; s.d. of one representative experiment out of three independent experiments. n &#x3d; 5 per group, <italic>p</italic>-values were calculated by one-way ANOVA (Tukey&#x2019;s test). &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-14-1236469-g002.tif"/>
</fig>
<p>Toll-like receptor 4 (TLR4), which is a classical pattern recognition receptor, plays a key role in the activation of innate immunity (<xref ref-type="bibr" rid="B49">Vijay, 2018</xref>; <xref ref-type="bibr" rid="B41">Sartorius et al., 2021</xref>). Mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-&#x3ba;B) are two crucial downstream signaling pathways, which contribute to TLR4-induced pro-inflammatory cytokine production (<xref ref-type="bibr" rid="B20">Kawasaki and Kawai, 2014</xref>; <xref ref-type="bibr" rid="B28">Manik and Singh, 2022</xref>). To determine the underlying anti-inflammatory mechanism of LMZ, we measured the expression and phosphorylation levels of p65 in NF-&#x3ba;B signal pathway, ERK1/2, p38 MAPK, and JNK in MAPK signal pathway in lung tissues of LPS-induced mice. The phosphorylation level of p65 in lung tissue was remarkably increased after LPS stimulation and gradually decreased after LMZ treatment (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>). To further confirm the negative regulator of LMZ in NF-&#x3ba;B pathway, we investigated the expression levels of NF-&#x3ba;B specific inhibitor I&#x3ba;B&#x3b1;, a classical inhibitor of NF-&#x3ba;B. As shown in <xref ref-type="fig" rid="F3">Figure 3C</xref>, the expression level of I&#x3ba;B&#x3b1; was decreased after LPS stimulation, while enhanced by co-administration with LMZ dose-dependently. Furthermore, the phosphorylated level of p38 MAPK, ERK1/2, and JNK increased significantly after LMZ treatment dose-dependently (<xref ref-type="fig" rid="F3">Figures 3D&#x2013;F</xref>). These results suggested that LMZ significantly attenuated the production of inflammatory cytokines through MAPK and NF-&#x3ba;B signal pathways in LPS-induced ALI mice.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Lomerizine (LMZ) suppressed inflammation through NK-&#x3ba;B and MAPK signal pathways in lipopolysaccharide (LPS)-induced acute lung injury mice. <bold>(A)</bold> The phosphorylation level of NF-&#x3ba;B and MAPK kinases by Western blotting. The ratios of the grayscale values of the bands, <bold>(B)</bold> phosphor-p65 (p-p65) and total p65, <bold>(C)</bold> I&#x3ba;B&#x3b1; and &#x3b2;-actin, <bold>(D)</bold> p-p38 and total p38, <bold>(E)</bold> p-JNK and total JNK and <bold>(F)</bold> p-ERK1/2 and total ERK1/2. Data shown mean &#xb1; s.d. of one representative experiment out of three independent experiments. n &#x3d; 5 per group, <italic>p</italic>-values were calculated by one-way ANOVA (Tukey&#x2019;s test). &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-14-1236469-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>3.3 Lomerizine inhibits the pro-inflammatory cytokine production through MAPK and NF-&#x3ba;B signal pathways in macrophages</title>
<p>To determine the role of inflammatory cytokines induced by LPS in macrophages, we detected the expression of inflammatory cytokines using RT-PCR and ELISA in BMDMs. The results showed that the mRNA levels of pro-inflammatory cytokines were dramatically upregulated in LPS-stimulated BMDMs compared to that of the PBS group, while the expression levels were downregulated with LMZ treatment dose-dependently (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref>). Similarly, the protein levels of TNF-&#x3b1;, IL-1&#x3b2; and IL-6 in macrophages increased after LPS challenge (<xref ref-type="fig" rid="F4">Figures 4D&#x2013;F</xref>). Furthermore, we also measured downstream mediators of inflammatory cytokines, inducible nitric oxide synthase (iNOS) and NO, expression levels in BMDMs. The expression levels of iNOS and the concentration of NO were significantly upregulated in BMDMs after LPS stimulation (<xref ref-type="fig" rid="F4">Figures 4G&#x2013;I</xref>). Compared with the LPS group, pre-treated with LMZ downregulated the expression of iNOS and NO dose-dependently. Furthermore, we measured the activity of NF-&#x3ba;B and MAPK signal pathways in LPS-induced macrophages pretreated with LMZ. Results showed that LMZ significantly inhibited the phosphorylated level of p65 and increased the protein level of I&#x3ba;B&#x3b1; (<xref ref-type="fig" rid="F5">Figures 5A&#x2013;C</xref>). Similarly, the phosphorylated level of p38 MAPK, JNK, ERK1/2 in MAPK signal pathway were significantly decreased after LMZ pretreatment in LPS-challenged BMDMs (<xref ref-type="fig" rid="F5">Figures 5D&#x2013;F</xref>). These results show that LMZ alleviated LPS-induced pro-inflammatory response through MAPK and NF-&#x3ba;B pathways.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Lomerizine (LMZ) inhibited the production of pro-inflammatory cytokines in macrophages. BMDMs were pretreated with LMZ (0, 3, 10 and 30&#xa0;&#x3bc;M) for 30&#xa0;min before 4&#xa0;h LPS challenge (100&#xa0;ng/mL). The mRNA expression levels of <italic>Tnf&#x3b1;</italic> <bold>(A)</bold>, <italic>Il1&#x3b2;</italic> <bold>(B)</bold> and <italic>Il6</italic> <bold>(C)</bold> in BMDM cell lysates were detected by RT-PCR. All groups were normalized to PBS group. The protein levels of TNF-&#x3b1; <bold>(D)</bold>, IL-1&#x3b2; <bold>(E)</bold> and IL-6 <bold>(F)</bold> in the supernatant of the culture medium were measured by ELISA kits. <bold>(G&#x2013;H)</bold> The protein levels of iNOS in BMDMs were tested by Western blotting. <bold>(I)</bold> NO levels in BMDMs were tested by NO assay kit. Data shown mean &#xb1; s. e.m of three independent experiments. <italic>p</italic>-values were calculated by one-way ANOVA (Tukey&#x2019;s test). &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-14-1236469-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Lomerizine (LMZ) decreased the phosphorylation levels of NF-&#x3ba;B and MAPK pathways in macrophages. BMDMs were pretreated with LMZ (0, 3, 10 and 30&#xa0;&#x3bc;M) for 30&#xa0;min before 4&#xa0;h LPS challenge (100&#xa0;ng/mL). <bold>(A)</bold> The phosphorylation levels of NF-&#x3ba;B and MAPK kinases in BMDM cell lysates by Western blotting. <bold>(B)</bold> p-p65 and total p65, <bold>(C)</bold> I&#x3ba;b&#x3b1; and &#x3b2;-actin, <bold>(D)</bold> p-p38 and total p38, <bold>(E)</bold> p-JNK and total JNK, <bold>(F)</bold> p-ERK1/2 and total ERK1/2. The ratio of grayscale values of the bands was quantified using ImageJ software. Data shown mean &#xb1; s. e.m of three independent experiments. <italic>p</italic>-values were calculated by one-way ANOVA (Tukey&#x2019;s test). &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-14-1236469-g005.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>3.4 Lomerizine reduces the expression of pro-inflammatory cytokines via the Ca<sup>2&#x2b;</sup> pathway in macrophages</title>
<p>LPS has been reported to promote Ca<sup>2&#x2b;</sup> influx in macrophages (<xref ref-type="bibr" rid="B7">Chen et al., 2001</xref>; <xref ref-type="bibr" rid="B23">Letari et al., 1991</xref>; <xref ref-type="bibr" rid="B54">Zhou et al., 2006</xref>). To determine the association between Ca<sup>2&#x2b;</sup> influx and pro-inflammatory cytokines expression in macrophages, we detected Ca<sup>2&#x2b;</sup> influx using a Fluo-4 AM green-fluorescent calcium indicator. Compared with PBS group, fluorescence intensity increased sharply within 2&#xa0;min after LPS or Ca<sup>2&#x2b;</sup> channel agonist Bay K8644 (BK) stimulation, which was decreased after LMZ pretreatment in BMDMs (<xref ref-type="fig" rid="F6">Figures 6A,B</xref>). Interestingly, we co-incubated LMZ with BK in LPS-induced BMDMs, the fluorescence intensity increased within 2&#xa0;min again. Moreover, the expression of <italic>Tnf&#x3b1;</italic>, <italic>Il1&#x3b2;</italic>, and <italic>Il6</italic> were successfully reduced by LMZ and reversed by BK treatment in BMDMs (<xref ref-type="fig" rid="F6">Figures 6C&#x2013;E</xref>). Namely, LMZ attenuated LPS-induced inflammation by inhibiting Ca<sup>2&#x2b;</sup> influx in BMDMs (<xref ref-type="fig" rid="F6">Figure 6F</xref>). These data suggested that the anti-inflammatory effect of LMZ rely on Ca<sup>2&#x2b;</sup> channels activation.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Lomerizine (LMZ) reduced the expression of pro-inflammatory cytokines via the Ca<sup>2&#x2b;</sup> pathway in macrophages. BMDMs were pretreated with Fluo-4 AM ester solution for 30&#xa0;min. Cells were then treated with LMZ alone or LMZ co-treated with Bay K8644 (BK, 10&#xa0;&#x3bc;M) before exposed to lipopolysaccharide (LPS, 100&#xa0;ng/mL). <bold>(A)</bold> Ca<sup>2&#x2b;</sup> was detected as fluorescent bright green using laser scanning confocal fluorescence microscopy in 10&#xa0;min in BMDMs. <bold>(B)</bold> Green fluorescence intensity was quantified. Scale bar, 100&#xa0;&#x3bc;m. BMDMs were pretreated with LMZ (10&#xa0;&#x3bc;M) alone or co-treated BK (10&#xa0;&#x3bc;M) and LMZ (10&#xa0;&#x3bc;M) followed by LPS stimulation for 4&#xa0;h. The mRNA levels of <italic>Tnf&#x3b1;</italic> <bold>(C)</bold>, <italic>Il1&#x3b2;</italic> <bold>(D)</bold> and <italic>Il6</italic> <bold>(E)</bold> were detected in BMDMs by RT-PCR. <bold>(F)</bold> Schematic illustration of possible mechanisms by which lomerizine (LMZ) inhibited acute lung injury mediated NF-&#x3ba;B and MAPK signaling in macrophages. Data shown mean &#xb1; s. e.m of three independent experiments. <italic>p</italic>-values were calculated by one-way ANOVA (Tukey&#x2019;s test). &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-14-1236469-g006.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<p>Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is an extremely hazardous pulmonary inflammatory syndrome. ALI is a respiratory system disease with respiratory distress with a PaO<sub>2</sub>/FiO<sub>2</sub> &#x2264; 300&#xa0;mmHg in clinical defined by American-European Consensus Committee (AECC) in 1994 (<xref ref-type="bibr" rid="B3">Bernard et al., 1994</xref>). The majority of acute lung injury models are constructed on the basis of their pathological characteristics, which include pulmonary neutrophil infiltration, hyaline membrane deposition, and microthrombus formation (<xref ref-type="bibr" rid="B31">Matute-Bello et al., 2008</xref>). LPS challenge is widely used to mimic human ALI. Upon intratracheal instillation with LPS in mice, the expression of proinflammatory cytokines reach the peak around 6&#xa0;h and then gradually declined, which could be used to determine the potential reagents to alleviate ALI (<xref ref-type="bibr" rid="B24">Li et al., 2012</xref>; <xref ref-type="bibr" rid="B19">Jing et al., 2015</xref>; <xref ref-type="bibr" rid="B51">Wu et al., 2018</xref>). Corticosteroids, an effective anti-inflammatory medicine, have been wildly used in treating ALI/ARDS. However, corticosteroids treatment is always associated with neuromuscular complications and may cause myoglobulin loss in severely ill patients (<xref ref-type="bibr" rid="B1">Amaya-Villar et al., 2005</xref>; <xref ref-type="bibr" rid="B36">Rady et al., 2006</xref>; <xref ref-type="bibr" rid="B26">Liu et al., 2013</xref>). In this study, we found that lomerizine (LMZ) significantly alleviated lipopolysaccharide (LPS)-induced ALI both <italic>in vitro</italic> and <italic>in vivo</italic>, which showed LMZ is a potential therapeutic drug for ALI/ARDS treatment.</p>
<p>Ca<sup>2&#x2b;</sup> influx is one of the most important cell signals for regulating various physiological and pathological processes, such as cancer, heart failure, diabetes and neurodegenerative disease (<xref ref-type="bibr" rid="B37">Rossi et al., 2019</xref>; <xref ref-type="bibr" rid="B48">Varghese et al., 2019</xref>). In recent years, accumulating literature have highlighted the link between Ca<sup>2&#x2b;</sup> influx and inflammation. Saddala et al. found that blocking Ca<sup>2&#x2b;</sup> influx inhibited the activation of calcineurin (CN) and recruitment of I&#x3ba;B kinases (IKK) through L-type voltage-gated calcium channel (L-VGCC), resulting in the inhibition of nuclear factor kappa B (NF-&#x3ba;B) activation (<xref ref-type="bibr" rid="B39">Saddala et al., 2020</xref>). Tauseef revealed that activated Ca<sup>2&#x2b;</sup> influx into endothelial cells (EC) via myeloid differentiation factor 88 (MyD88) and NF-&#x3ba;B pathway eventually inducing inflammation (<xref ref-type="bibr" rid="B46">Tauseef et al., 2012</xref>). Here, we validated the inflammatory therapeutic effect of LMZ on ALI by using LPS-induced ALI mice. Furthermore, In LPS-stimulated BMDMs, LMZ treatment significantly inhibited pro-inflammatory cytokines expression. While the Bay K8644 (BK) treatment significantly increased inflammatory cytokines expression, which were suppressed by LMZ. These results indicated that LMZ inhibited the pro-inflammatory process via Ca<sup>2&#x2b;</sup> influx, providing evidence for studying the relationship between Ca<sup>2&#x2b;</sup> influx and inflammation.</p>
<p>Activation of mitogen-activated protein kinase (MAPK) and NF-&#x3ba;B signaling pathways increase the expression of cytokines in pneumonia and aggravate ALI. The activation of MAPK can promote the induction of inflammatory factors, COX-2 and iNOS, thus up-regulating the inflammatory reactivity (<xref ref-type="bibr" rid="B8">Choi et al., 2009</xref>; <xref ref-type="bibr" rid="B5">Bhatt et al., 2010</xref>). Several studies have shown that LPS binding to TLR4 activates downstream NF-&#x3ba;B and MAPK signaling pathways in macrophages (<xref ref-type="bibr" rid="B27">Lu et al., 2008</xref>; <xref ref-type="bibr" rid="B25">Li et al., 2015</xref>). I&#x3ba;B&#x3b1; is an essential negative signaling factor in NF-&#x3ba;B signaling pathway, which segregates NF-&#x3ba;B and p65 complex (<xref ref-type="bibr" rid="B44">Solt and May 2008</xref>; <xref ref-type="bibr" rid="B33">Oeckinghaus and Ghosh, 2009</xref>). LMZ decreased the phosphorylation level of p65 in NF-&#x3ba;B and p38 MAPK, JNK, and ERK1/2 in MAPK pathway and increased the expression level of I&#x3ba;B&#x3b1; in BMDMs. Our results demonstrated that LMZ ameliorated ALI by inhibiting inflammatory signaling through the MAPK and NF-&#x3ba;B pathways in macrophages which could guide future studies in this area.</p>
<p>Previous studies have found therapeutic effects of lomerizine (LMZ) in cardiovascular diseases. Shimazawa et al. found that LMZ inhibited hypoperfusion and expression of c-Fos-like immunoreactivity on the cortical to treat migraine (<xref ref-type="bibr" rid="B43">Shimazawa et al., 1995</xref>). Concerning the protective effects of lomerizine on neuronal, Toriu et al. found that LMZ protected neuronal cells by inhibiting glutamate-induced neurotoxicity, ischemia, and reperfusion damage (<xref ref-type="bibr" rid="B47">Toriu et al., 2000</xref>). Moreover, Fitzgerald et al. validated the therapeutic effect of LMZ in optic nerve (ON) injury rats by inhibiting L-type calcium channels on the RGC (<xref ref-type="bibr" rid="B11">Fitzgerald et al., 2009</xref>). The role of LMZ in apoptosis is intriguing, but we did not find LMZ to induce apoptosis in our dose range, which is consistent with existing studies (<xref ref-type="bibr" rid="B18">Ito et al., 2010</xref>; <xref ref-type="bibr" rid="B34">Park et al., 2023</xref>). In this study, we found that LMZ alleviates acute lung injury by decreasing expression of inflammatory factors in macrophages which broadens the potential applications of LMZ in the field of pulmonary inflammatory diseases.</p>
<p>In conclusion, our data reveal an injury-preventive role of LMZ in the LPS-induced mice model. We found that LMZ inhibited the phosphorylation level of the NF-&#x3ba;B and MAPK pathway by blocking Ca<sup>2&#x2b;</sup> influx in macrophages, thereby reducing the release of pro-inflammatory factors, indicating that it is a potential agent in treating acute lung injury.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6">
<title>Ethics statement</title>
<p>The animal study was approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University (A2018075). The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>YS, XA and FQ conceived the study. YS, YG, YC, HZ, DC, and WZ designed, performed, and interpreted experimental data. YG, YC, and HZ analyzed database. YS, FQ, YS and YG wrote the paper. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>The present study was supported by Science and Technology Development Fund of Shanghai Pudong New Area (grant no. PKJ2021-Y35), the Science and Technology Commission of Shanghai Municipality (grant no. 20Z11901004, 20Z11901000), the National Natural Science Foundation of China (81973329, 82173821, 82072142), the Discipline Construction Promoting Project of Shanghai Pudong Hospital (grant no. Zdzk 2020-11), the Program for the Academic Leader in Health Committee of Shanghai (grant no. 21XD1403000) and the Medical discipline construction project of Pudong Health Committee of Shanghai (grant no PWYts2021-14).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amaya-Villar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garnacho-Montero</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Garmend&#xed;a</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Madrazo-Osuna</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Garnacho-Montero</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Luque</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease</article-title>. <source>Intensive Care Med.</source> <volume>31</volume> (<issue>1</issue>), <fpage>157</fpage>&#x2013;<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-004-2509-9</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arora</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Irshad</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rafat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>TLRs in pulmonary diseases</article-title>. <source>Life Sci.</source> <volume>233</volume>, <fpage>116671</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2019.116671</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernard</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Artigas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brigham</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Carlet</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Falke</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>1994</year>). <article-title>Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. the consensus committee</article-title>. <source>Intensive Care Med.</source> <volume>20</volume> (<issue>3</issue>), <fpage>225</fpage>&#x2013;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1007/BF01704707</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernard</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Luce</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Sprung</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Rinaldo</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Tate</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Sibbald</surname>
<given-names>W. J.</given-names>
</name>
<etal/>
</person-group> (<year>1987</year>). <article-title>High-dose corticosteroids in patients with the adult respiratory distr ess syndrome</article-title>. <source>N. Engl. J. Med.</source> <volume>317</volume> (<issue>25</issue>), <fpage>1565</fpage>&#x2013;<lpage>1570</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198712173172504</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatt</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Dahiya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sodhi</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Protein kinase Cdelta and protein tyrosine kinase regulate peptidoglycan-induced nuclear factor-kappaB activation and inducible nitric oxide synthase expression in mouse peritoneal macrophages <italic>in vitro</italic>
</article-title>. <source>Mol. Immunol.</source> <volume>47</volume> (<issue>4</issue>), <fpage>861</fpage>&#x2013;<lpage>870</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2009.10.029</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butt</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kurdowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>T. C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Acute lung injury: A clinical and molecular review</article-title>. <source>Arch. Pathol. Lab. Med.</source> <volume>140</volume> (<issue>4</issue>), <fpage>345</fpage>&#x2013;<lpage>350</lpage>. <pub-id pub-id-type="doi">10.5858/arpa.2015-0519-RA</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W. W.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Involvement of protein kinases in the potentiation of lipopolysaccharide-induced inflammatory mediator formation by thapsigargin in peritoneal macrophages</article-title>. <source>J. Leukoc. Biol.</source> <volume>69</volume> (<issue>2</issue>), <fpage>280</fpage>&#x2013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.69.2.280</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells</article-title>. <source>Br. J. Pharmacol.</source> <volume>156</volume> (<issue>6</issue>), <fpage>933</fpage>&#x2013;<lpage>940</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00022.x</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Van Wagoner</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Plow</surname>
<given-names>E. F.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>L-type calcium channel blockers exert an antiinflammatory effect by suppressing expression of plasminogen receptors on macrophages</article-title>. <source>Circ. Res.</source> <volume>105</volume> (<issue>2</issue>), <fpage>167</fpage>&#x2013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.200311</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Slutsky</surname>
<given-names>A. S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Acute respiratory distress syndrome: advances in diagnosis and treatment</article-title>. <source>JAMA</source> <volume>319</volume> (<issue>7</issue>), <fpage>698</fpage>&#x2013;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.21907</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzgerald</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Evill</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Dunlop</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>50</volume> (<issue>11</issue>), <fpage>5456</fpage>&#x2013;<lpage>5462</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.09-3717</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Y. D.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Kursat Azkur</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Azkur</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Risk factors for severe and critically ill COVID-19 patients: A review</article-title>. <source>Allergy</source> <volume>76</volume> (<issue>2</issue>), <fpage>428</fpage>&#x2013;<lpage>455</lpage>. <pub-id pub-id-type="doi">10.1111/all.14657</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gattinoni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Collino</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maiolo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rapetti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tonetti</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>The future of mechanical ventilation: lessons from the present and the past</article-title>. <source>Crit. Care</source> <volume>21</volume> (<issue>1</issue>), <fpage>183</fpage>&#x2013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1186/s13054-017-1750-x</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gattinoni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tonetti</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cressoni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cadringher</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Moerer</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Ventilator-related causes of lung injury: the mechanical power</article-title>. <source>Intensive Care Med.</source> <volume>42</volume> (<issue>10</issue>), <fpage>1567</fpage>&#x2013;<lpage>1575</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-016-4505-2</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Gaudilliere</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Berna</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2000</year>). <source>Section VII. Trends and perspectives</source>. <publisher-loc>Amsterdam, Netherlands</publisher-loc>: <publisher-name>Elsevier</publisher-name>.</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Regulatory T cell and macrophage crosstalk in acute lung injury: future perspectives</article-title>. <source>Cell Death Discov.</source> <volume>9</volume> (<issue>1</issue>), <fpage>9</fpage>. <pub-id pub-id-type="doi">10.1038/s41420-023-01310-7</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection</article-title>. <source>PLoS One</source> <volume>9</volume> (<issue>3</issue>), <fpage>e91167</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0091167</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tsuruma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shimazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Araie</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Lomerizine, a Ca2&#x2b; channel blocker, protects against neuronal degenera tion within the visual center of the brain after retinal damage in mic e</article-title>. <source>CNS Neurosci. Ther.</source> <volume>16</volume> (<issue>2</issue>), <fpage>103</fpage>&#x2013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5949.2009.00081.x</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jing</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chunhua</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shumin</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Effects of acteoside on lipopolysaccharide-induced inflammation in acu te lung injury via regulation of NF-&#x3ba;B pathway <italic>in vivo</italic> and <italic>in vitro</italic>
</article-title>. <source>Toxicol. Appl. Pharmacol.</source> <volume>285</volume> (<issue>2</issue>), <fpage>128</fpage>&#x2013;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2015.04.004</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Toll-like receptor signaling pathways</article-title>. <source>Front. Immunol.</source> <volume>5</volume>, <fpage>461</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00461</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolaczkowska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kubes</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Neutrophil recruitment and function in health and inflammation</article-title>. <source>Nat. Rev. Immunol.</source> <volume>13</volume> (<issue>3</issue>), <fpage>159</fpage>&#x2013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1038/nri3399</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>J. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The role of macrophages in the development of acute and chronic inflammatory lung diseases</article-title>. <source>Cells</source> <volume>10</volume> (<issue>4</issue>), <fpage>897</fpage>. <pub-id pub-id-type="doi">10.3390/cells10040897</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letari</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Nicosia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chiavaroli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vacher</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schlegel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Activation by bacterial lipopolysaccharide causes changes in the cytosolic free calcium concentration in single peritoneal macrophages</article-title>. <source>J. Immunol.</source> <volume>147</volume> (<issue>3</issue>), <fpage>980</fpage>&#x2013;<lpage>983</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.147.3.980</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats</article-title>. <source>J. Inflamm.</source> <volume>9</volume> (<issue>1</issue>), <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/1476-9255-9-33</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kosturakis</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Cassidy</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kennamer-Chapman</surname>
<given-names>R. M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy</article-title>. <source>Brain Behav. Immun.</source> <volume>49</volume>, <fpage>255</fpage>&#x2013;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.06.003</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ahmet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Krishnamoorthy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mandelcorn</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Leigh</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy</article-title>. <source>Allergy, Asthma &#x26; Clin. Immunol.</source> <volume>9</volume> (<issue>1</issue>), <fpage>30</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1186/1710-1492-9-30</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>W. C.</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>P. S.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>LPS/TLR4 signal transduction pathway</article-title>. <source>Cytokine</source> <volume>42</volume> (<issue>2</issue>), <fpage>145</fpage>&#x2013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2008.01.006</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19</article-title>. <source>J. Med. Virol.</source> <volume>94</volume> (<issue>3</issue>), <fpage>869</fpage>&#x2013;<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.27405</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamagishi</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>396</volume> (<issue>2</issue>), <fpage>566</fpage>&#x2013;<lpage>570</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2010.04.149</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthay</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Zemans</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Arabi</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Beitler</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Mercat</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Acute respiratory distress syndrome</article-title>. <source>Nat. Rev. Dis. Prim.</source> <volume>5</volume> (<issue>1</issue>), <fpage>18</fpage>. <pub-id pub-id-type="doi">10.1038/s41572-019-0069-0</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matute-Bello</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Frevert</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>T. R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Animal models of acute lung injury</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source> <volume>295</volume> (<issue>3</issue>), <fpage>L379</fpage>&#x2013;<lpage>L399</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00010.2008</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Gattinoni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Calfee</surname>
<given-names>C. S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Acute respiratory distress syndrome</article-title>. <source>Lancet</source> <volume>398</volume> (<issue>10300</issue>), <fpage>622</fpage>&#x2013;<lpage>637</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00439-6</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oeckinghaus</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The NF-kappaB family of transcription factors and its regulation</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>1</volume> (<issue>4</issue>), <fpage>a000034</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a000034</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Effect of magnetic microparticles on cultivated human corneal endothelial cells</article-title>. <source>Front. Immunol.</source> <volume>12</volume>, <fpage>14</fpage>. <pub-id pub-id-type="doi">10.1167/tvst.12.2.14</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfortmueller</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Spinetti</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Urman</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Luedi</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Schefold</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>COVID-19-associated acute respiratory distress syndrome (CARDS): current knowledge on pathophysiology and ICU treatment - a narrative review</article-title>. <source>Best. Pract. Res. Clin. Anaesthesiol.</source> <volume>35</volume> (<issue>3</issue>), <fpage>351</fpage>&#x2013;<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpa.2020.12.011</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rady</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Helmers</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Corticosteroids influence the mortality and morbidity of acute critical illness</article-title>. <source>Crit. Care</source> <volume>10</volume> (<issue>4</issue>), <fpage>R101</fpage>&#x2013;<lpage>R109</lpage>. <pub-id pub-id-type="doi">10.1186/cc4971</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pizzo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Filadi</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Calcium, mitochondria and cell metabolism: A functional triangle in bi oenergetics</article-title>. <source>Biochim. Biophys. Acta Mol. Cell Res.</source> <volume>1866</volume> (<issue>7</issue>), <fpage>1068</fpage>&#x2013;<lpage>1078</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2018.10.016</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubenfeld</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Peabody</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Neff</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Incidence and outcomes of acute lung injury</article-title>. <source>N. Engl. J. Med.</source> <volume>353</volume> (<issue>16</issue>), <fpage>1685</fpage>&#x2013;<lpage>1693</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa050333</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saddala</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Lennikov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mukwaya</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Lagali</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Discovery of novel L-type voltage-gated calcium channel blockers and application for the prevention of inflammation and angiogenesis</article-title>. <source>J. Neuroinflammation</source> <volume>17</volume> (<issue>1</issue>), <fpage>132</fpage>&#x2013;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1186/s12974-020-01801-9</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saqib</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Suk</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mohammad</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Baig</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Savai</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Phytochemicals as modulators of M1-M2 macrophages in inflammation</article-title>. <source>Oncotarget</source> <volume>9</volume> (<issue>25</issue>), <fpage>17937</fpage>&#x2013;<lpage>17950</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.24788</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sartorius</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Trovato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Manco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>D&#x2019;Apice</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Berardinis</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines</article-title>. <source>npj Vaccines</source> <volume>6</volume> (<issue>1</issue>), <fpage>127</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-021-00391-8</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shima</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Katsube</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kitagawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hato</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hino</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Calcium channel blockers suppress cytokine-induced activation of human neutrophils</article-title>. <source>Am. J. Hypertens.</source> <volume>21</volume> (<issue>1</issue>), <fpage>78</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/ajh.2007.13</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Watano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sukamoto</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Effects of Ca2&#x2b; channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats</article-title>. <source>Br. J. Pharmacol.</source> <volume>115</volume> (<issue>8</issue>), <fpage>1359</fpage>&#x2013;<lpage>1368</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1995.tb16624.x</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solt</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>May</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The IkappaB kinase complex: master regulator of NF-kappaB signaling</article-title>. <source>Immunol. Res.</source> <volume>42</volume> (<issue>1-3</issue>), <fpage>3</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-008-8025-1</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinberg</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>L. D.</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Hough</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Lanken</surname>
<given-names>P. N.</given-names>
</name>
<name>
<surname>Hyzy</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Efficacy and safety of corticosteroids for persistent acute respirator y distress syndrome</article-title>. <source>N. Engl. J. Med.</source> <volume>354</volume> (<issue>16</issue>), <fpage>1671</fpage>&#x2013;<lpage>1684</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa051693</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tauseef</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Knezevic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chava</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sukriti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gianaris</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>TLR4 activation of TRPC6-dependent calcium signaling mediates endotoxi n-induced lung vascular permeability and inflammation</article-title>. <source>J. Exp. Med.</source> <volume>209</volume> (<issue>11</issue>), <fpage>1953</fpage>&#x2013;<lpage>1968</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20111355</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toriu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Akaike</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yasuyoshi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kashii</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Lomerizine, a Ca2&#x2b; channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina</article-title>. <source>Exp. Eye Res.</source> <volume>70</volume> (<issue>4</issue>), <fpage>475</fpage>&#x2013;<lpage>484</lpage>. <pub-id pub-id-type="doi">10.1006/exer.1999.0809</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varghese</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Samuel</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Sadiq</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kubatka</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liskova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Benacka</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Anti-cancer agents in proliferation and cell death: the calcium connection</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume> (<issue>12</issue>), <fpage>3017</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20123017</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vijay</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Toll-like receptors in immunity and inflammatory diseases: past, present, and future</article-title>. <source>Int. Immunopharmacol.</source> <volume>59</volume>, <fpage>391</fpage>&#x2013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2018.03.002</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Misharin</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Budinger</surname>
<given-names>G. R. S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The role of macrophages in the resolution of inflammation</article-title>. <source>J. Clin. Invest.</source> <volume>129</volume> (<issue>7</issue>), <fpage>2619</fpage>&#x2013;<lpage>2628</lpage>. <pub-id pub-id-type="doi">10.1172/JCI124615</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>MK2 mediates macrophage activation and acute lung injury by regulating let-7e miRNA</article-title>. <source>Am. J. Physiology-Lung Cell. Mol. Physiology</source> <volume>315</volume> (<issue>3</issue>), <fpage>371</fpage>&#x2013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00019.2018</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y. X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>B. B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Ethyl ferulate protects against lipopolysaccharide-induced acute lung injury by activating AMPK/Nrf2 signaling pathway</article-title>. <source>Acta Pharmacol. Sin.</source> <volume>42</volume> (<issue>12</issue>), <fpage>2069</fpage>&#x2013;<lpage>2081</lpage>. <pub-id pub-id-type="doi">10.1038/s41401-021-00742-0</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wynn</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Chawla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pollard</surname>
<given-names>J. W.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Macrophage biology in development, homeostasis and disease</article-title>. <source>Nature</source> <volume>496</volume> (<issue>7446</issue>), <fpage>445</fpage>&#x2013;<lpage>455</lpage>. <pub-id pub-id-type="doi">10.1038/nature12034</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Ca2&#x2b;- and protein kinase C-dependent signaling pathway for nuclear factor-kappaB activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide-stimulated rat peritoneal macrophages</article-title>. <source>J. Biol. Chem.</source> <volume>281</volume> (<issue>42</issue>), <fpage>31337</fpage>&#x2013;<lpage>31347</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M602739200</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>